Vanguard Capital Management’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
Other funds holding FULC
Vanguard Capital Management's FULC Position: Q3 2026 in Review
Vanguard Capital Management increased its Fulcrum Therapeutics (FULC) stake by 6.2% in Q3 2026, buying an estimated $631K and bringing the position to 2,865,304 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2721.
Vanguard Capital Management first reported a position in FULC in Q1 2026 and has held it in 3 quarters since. The position peaked at $20.7M in Q1 2026. 151 funds tracked by Wall St. Rank hold FULC as of Q3 2026.
- Vanguard Capital Management held 2,865,304 shares of Fulcrum Therapeutics worth $10.6M as of Q3 2026.
- Vanguard Capital Management bought 168,088 Fulcrum Therapeutics shares in Q3 2026, an estimated $631K.
- Fulcrum Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2721 holding.
- Vanguard Capital Management first reported a position in Fulcrum Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Fulcrum Therapeutics position peaked at $20.7M in Q1 2026.
- 151 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.